Targeting PRAME for acute myeloid leukemia therapy

By Jinjun Yang, Mengran Chen, Jing Ye, Hongbing Ma. 2024

Subfields: Hematology, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “…antigen receptor (CAR) T cells or peptide vaccines, have shown efficacy in other PRAME-expressing malignancies, including melanoma and acute myeloid leukemia [28] as stages, supports its suitability for targeted interventions; however, clinical trials are needed to validate this approach in SGCs.”